Therapy, Toxics and drugs

• anthracyclines
  13 May 2008

  References
  Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008 Apr;14(4):141-51. PMID: #18353726#

• GSK-3 inhibitors
  12 May 2008

  cyclin-dependent kinase (CDK)/glycogen synthase kinase-3 (GSK-3) inhibitors

• Nutlin-3A
  29 February 2008

  Nutlin 3A

• anti-cancer drugs
  31 January 2008

  cancer drugs

• sialidase inhibitors
  21 January 2008

  References
  von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007 Dec;6(12):967-74. PMID: #18049471#

• omalizumab
  20 January 2008

  References
  Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006 Jun 22;354(25):2689-95. PMID: #16790701#

• BCR-ABL inhibitors
  20 January 2008

  BCR-ABL tyrosine kinase inhibitors

• VEGF-targeted therapy
  16 January 2008

  VEGF-targeted cancer therapy; anti-VEGF/VEGFR therapies

• gene-directed enzyme-prodrug therapy
  6 January 2008

  Gene-directed enzyme-prodrug therapy (GDEPT)

• thiopurines
  6 January 2008

  Thiopurines have diverse clinical applications and their long-term use as anti-rejection drugs in transplant patients has been associated with a significantly increased risk of various types of cancer.
  Although they are slowly being replaced by a new generation of non-thiopurine immunosuppressants, it is anticipated that their use in the management of inflammatory and autoimmune diseases will continue to increase.
  References
  Karran P, Attard N. Thiopurines in current medical practice: (...)

0 | ... | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | ... | 170